Piper Sandler Maintains Overweight on Avalo Therapeutics, Raises Price Target to $60

Piper Sandler analyst Yasmeen Rahimi maintains Avalo Therapeutics (NASDAQ:AVTX) with a Overweight and raises the price target from $48 to $60.